GlaxoSmithKline Gets Covifenz Covid-19 Vaccine Approval in Canada
February 24 2022 - 10:59AM
Dow Jones News
By Sabela Ojea
GlaxoSmithKline PLC said Thursday that Health Canada has
approved its Covifenz Covid-19 vaccine.
The British pharma major said the plant-based Covid-19 vaccine
was developed along with the Canadian biopharmaceutical company
Medicago Inc.
"We're...grateful for the Government of Canada's support in the
development of this new vaccine, and we are manufacturing doses to
start fulfilling its order," said Takashi Nagao, president and
Chief Executive of Medicago.
Medicago has a contract with the Government of Canada,
GlaxoSmithKline said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
February 24, 2022 10:44 ET (15:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024
